Association of serum Rituximab (IDEC-C2B8) concentration and anti- tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

Annals of Oncology

Volumn 9, Issue 9, 1998, Pages 995-1001

  Berinstein, N L ^a,h   Grillo Lopez A J ^b   White, C A ^b   Bence Bruckler, I ^c   Maloney, D ^d   Czuczman, M ^e   Green, D ^f   Rosenberg, J ^b   McLaughlin, P ^g   Shen, D ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b BIOGEN   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d USA   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

C2B8; Follicular lymphoma; IDEC; Immunotherapy; Low grade; MABTHERA; Monoclonal antibody; Rituxan

Indexed keywords

ALEMTUZUMAB; CHIMERIC ANTIBODY; MONOCLONAL ANTIBODY; RUTIXIMAB; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SCREENING; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR VOLUME;

EID: 7844225540     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008416911099     Document Type: Article

References (27)

1. Dillman R. Antibodies as cytotoxic therapy. J Clin Oncol 119; 12: 1497-515.
2. Meeker T, Lowder J, Maloney D et al. A clinical trial of antiidiotype therapy for B cell malignancy. Blood 1985; 65: 1349-63.
3. Brown S, Miller R, Horning S et al. Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon. Blood 1989; 73: 651-61.
4. Maloney D, Brown S, Czerwinski D et al. Monoclonal antiidiotype antibody therapy of B-cell lymphoma: The addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 1992; 80: 1502-10.
5. Tang S, Hewitt K, Reis M, Berinstein N. Immunosuppressive toxicity of CAMPATH IH monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymph 1996; 24: 930191.
6. Scheuemann R, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymph 1995; 18: 385-97.
7. Press O, Appelbaum F, Ledbetter J et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B-cell lymphomas. Blood 1987; 69: 584-91.
8. Press O, Eary J, Appelbaum F et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219-24.
9. 131I] anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459-65.
10. Grillo-López A, Chinn P, Morena R et al. Phase I study of IDEC-Y2B8: 90-yttrium labeled anti-CD20 monoclonal antibody therapy of relapsed non-Hodgkin's lymphoma. Blood 1995; 86: 55a.
11. Grillo-López A, Chinn P, Morena R et al. Treatment of relapsed non-Hodgkin's lymphoma (NHL) using the 90-Yttrium (90-Y) labeled anti-CD20 monoclonal antibody (Mab) IDEC-Y2B8: A phase I clinical trial. Ann Oncol 1996; 7: 57.
12. 90Yttrium anti-CD20 radioimmunotherapy of relapsed non-Hodgkin's lymphoma (NHL): Interim results of a phase I-II trial. San Diego, CA: American Society of Hematology 1997.
13. 111In antiCD20 in patients with low and intermediate grade B-cell non-Hodgkin's lymphoma (NHL) emphasis on bone marrow (BM). San Diego, CA: American Society of Hematology 1997.
14. Reff M, Garner K, Chambers K et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
15. Liu A, Robinson R, Murray J et al. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol 1987; 139: 3521-6.
16. LoBuglio A, Wheeler R, Trang J et al. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response. Proc Natl Acad Sci USA 1989; 86: 4220-4.
17. Mueller B, Romerdahl C, Gillies S, Reisfeld R. Enhancement of antibody dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990; 144: 1382.
18. Maloney D, Liles T, Czerwinski D et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457 66.
19. McLaughlin P, Cabanillas F, Grillo-López A et al. IDEC-C2B8 anti-CD20 antibody: Final report on a phase III pivotal trial in patients with relapsed low-grade or follicular lymphoma. Blood 1996; 88: 90a.
20. Maloney D, Grillo-Lopez A, White C et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188 95.
21. Grillo-López A, Horning S, Cheson B et al. Development of response criteria for low-grade or follicular lymphomas and application in a 166 patient study. Exp Hematol 1997; 25: 732.
22. Osterborg A, Dyer M, Bunjes D et al. Phase II multicentre study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-IH treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567 74.
23. Hekman A, Honselaar A, Vuist W et al. Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother 1991; 32: 364-72.
24. Remlinger K, Martin P, Hansen J etal. Murine monoclonal antiT-cell antibodies for the treatment of steroid resistant acute graft-versus-host disease. Hum Immunol 1984; 9: 21.
25. Hu E, Epstein A, Naeve G et al. A phase la clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies. Hemalological Oncol 1989; 7: 155-66.
26. Hale G, Clark M, Marcus R et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394-9.
27. Knox S, Hoppe R, Maloney D et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996; 87: 893-9.